Trial Profile
Multi-center, 2 year, non-interventional study, evaluating the efficacy of Lucentis (ranibizumab) treat-and-extend regime for the treatment of neovascular age-related macular degeneration in UK NHS ophthalmology clinics
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Novartis
- 26 Jul 2016 New trial record